Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

By Yuichi Ando, Hideo Saka, M. Ando, T. Sawa, K. Muro, H. Ueoka, A. Yokoyama, S. Saitoh, K. Shimokata, Yoshinori Hasegawa. Cancer Research, 2000

834 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. (2003, background): “Clinical toxicity has been reported in individuals with polymorphisms in UGT1A1 (Gilbert syndrome) when treated with irinotecan (CPT-11) (Ando et al., 2000).”
Pharmacogenomics and individualized drug therapy. (2006, background): “Patients homozygous or heterozygous for seven TA repeats have a sevenfold higher likelihood of diarrhea and/or leukopenia with irinotecan therapy than do patients with the wild-type genotype (six TA repeats) (68, 69, 71).”
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). (2001, unknown): “On the basis of the relative importance of the systemic glucuronidation and the existence of genetic polymorphism, it has been proposed that UGT1A1 genotyping might be an approach to individualize CPT-11 treatment schedules (68, 73).”